ACCESSWIRE

Nutriband Inc.

Share
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl

ORLANDO, FL / ACCESSWIRE / June 20, 2024 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) provides an update on its Aversa Fentanyl product development program to shareholders as it aims to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to NDA filing.

  • As previously reported, the Company with its partner Kindeva Drug Delivery completed the feasibility agreement and entered into a commercial development and clinical supply agreement to manufacture product for the human abuse potential clinical study in support of a New Drug Application (NDA) to be submitted to FDA. The feasibility agreement was focused on adapting Kindeva's commercial transdermal manufacturing process to incorporate AVERSA™ abuse deterrent transdermal technology.
  • Nutriband is currently working with its partner Kindeva Drug Delivery to develop the commercial scale manufacturing process for the final product which will incorporate Nutriband's AVERSA™ abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch system.
  • Recently, Kindeva Drug Delivery completed the validation of the aversive agent cleaning analytical methods required to allow work with the aversive agents, denatonium benzoate and capsaicin, on the commercial manufacturing line.
  • Once the final commercial product manufacturing process is completed, Nutriband intends to file an IND with the FDA and perform the pivotal laboratory and clinical evaluations to demonstrate the abuse-deterrent properties of AVERSA Fentanyl, in compliance with FDA Guidance.
  • Nutriband will file an Investigational New Drug (IND) application with the FDA prior to conducting the single Phase 1 human abuse potential clinical study required for its NDA. The IND will include the chemistry, manufacturing, and controls (CMC) information for the commercial product as well as the clinical study protocol for the human abuse potential study.
  • No Phase 2 or phase 3 Clinical Trials are required prior to submitting for approval.
  • AVERSA(TM) Fentanyl is estimated to have the potential to reach peak annual US sales of $80 million to $200 million, according to a market analysis report from Health Advances(1).

The pivotal laboratory assessment to be conducted is a series of in vitro manipulation and extraction studies designed to determine if the potentially abuse-deterrent properties of the product can be defeated or compromised based on physical and chemical manipulation of the product. Preliminary studies conducted to date have shown that the AVERSA technology is very difficult to defeat by various physical or chemical means.

The pivotal clinical study is a human abuse potential study performed to assess the impact of the potentially abuse-deterrent properties in a drug-experienced, recreational user population. The human abuse potential study is a randomized, double-blind, placebo-controlled and positive controlled crossover study comparing AVERSA Fentanyl to the currently marketed fentanyl patch which does not contain abuse-deterrent technology. The success of the human abuse potential study is based on the assessment drug liking using various instruments that are predictive of the likelihood of abuse.

Nutriband's AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.

(1) Health Advances Aversa Fentanyl market analysis report 2022

About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

About Kindeva
Headquartered in Woodbury, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, intradermal drug delivery (microneedles) and connected drug delivery. Kindeva employs approximately 1,000 people worldwide. For more information, visit www.kindevadd.com.

Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:
RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-407-644-4256

Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: Support@nutriband.com

SOURCE: Nutriband Inc.



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESSWIRE

DK

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

Tamkeen Launches ‘Bahrain Skills and Gender Parity Accelerator’ at Davos22.1.2025 14:00:00 CET | Press release

DAVOS, SWITZERLAND / ACCESS Newswire / January 22, 2025 / The Bahrain Labour Fund (Tamkeen) has partnered with the World Economic Forum (WEF) to launch the Bahrain Skills and Gender Parity Accelerator. The announcement was made at Davos, exemplifying the theme of the 55th Annual Meeting "Collaboration for the Intelligent Age," wherein the data-driven accelerator is aimed at closing the gender skills gap in high-growth industries and at increasing the participation of the current and next generation of the local Bahraini workforce. In the presence of His Highness Shaikh Isa bin Salman bin Hamad Al Khalifa, the Chairman of the Board of Trustees of the Isa bin Salman Education Charitable Trust and Chairman of the Board of Directors the Labour Fund (Tamkeen) and H.E. Shaikh Salman bin Khalifa Al Khalifa, Minister of Finance and National Economy, alongside other key dignitaries; the agreement was signed by H.E. Noor bint Ali Alkhulaif, Minister of Sustainable Development, Chief Executive of

Preservica Academy Launches to Help Information Professionals Accelerate Skills in Active Digital Preservation22.1.2025 09:00:00 CET | Press release

BOSTON, MA and OXFORD, UK / ACCESS Newswire / January 22, 2025 / Preservica, a pioneer of Active Digital Preservation™ archiving, which applies intelligent, embedded and automated preservation to ensure always readable and trusted long-term data, is excited to announce the launch of the Preservica Academy. Delivering a flexible and comprehensive learning program, the Academy is designed to equip both newcomers and seasoned professionals with the skills and expertise needed to safeguard the accessibility and integrity of digital records into the future. The Academy focuses on practical, transferable skills in Active Digital Preservation™, including how to automate preservation actions and how to make Digital Preservation an embedded part of everyday workflows. The aim is to empower participants to enhance their professional development, unlock new career opportunities and master the art of preserving digital records for the long-term. "Preservica Academy is designed for Digital Preserva

Glenmorgan Investments Reopens Digital Asset Innovation Fund22.1.2025 08:00:00 CET | Press release

Glenmorgan Investments Announces the Reopening of Its Digital Asset Innovation Fund to New Investors Following Record-Breaking Performance and Enhanced Regulatory Clarity LONDON, UK / ACCESS Newswire / January 22, 2025 / Glenmorgan Investments Limited, a leading provider of award-winning fund management services since 1999, has announced the reopening of its highly sought-after Digital Asset Innovation Fund to new investors. The fund, which was initially capped in March 2024 due to unprecedented demand, will now have its cap increased to $1 billion from the original $500 million limit, following significant performance milestones and enhanced regulatory clarity in the digital asset landscape. The Digital Asset Innovation Fund, launched in 2018, has delivered exceptional returns, achieving record-breaking performance in 2024 and into 2025. The fund focuses on high-growth opportunities within the digital asset space, including cryptocurrencies and blockchain technology. Amid growing inte

The Now Corporation (OTC:NWPN) Subsidiary, Green Rain Solar Inc., Explores Selling Development Rights for Solar Farm Project in Greece, NY22.1.2025 08:00:00 CET | Press release

PASADENA, CA / ACCESS Newswire / January 22, 2025 / The Now Corporation (OTC PINK:NWPN) through its subsidiary, Green Rain Solar Inc., is actively exploring the sale of development rights for a groundbreaking solar energy project located at 4777 Dewey Avenue, Greece, New York. This strategic move aims to generate funding for the advancement of solar energy projects nationwide. The 19.5-acre site in Greece, NY, is set to host a state-of-the-art ground-mount solar farm. This initiative underscores Green Rain Solar's commitment to developing innovative and sustainable energy solutions that accelerate the transition to net-zero carbon emissions. Green Rain Solar, specializing in urban and distributed solar energy systems, seeks to transform underutilized spaces into renewable energy powerhouses. The sale of development rights for this project will provide the capital needed to enhance further solar initiatives, expand operations, and support clean energy adoption in high-demand regions. "T

ZeroPath Corp. Launches Next-Generation Code Security Platform Powered by Artificial Intelligence22.1.2025 03:00:00 CET | Press release

ZeroPath Security Scanner Launches to Market, Bringing Enterprise-Grade AI Security Analysis to Development Teams SAN FRANCISCO, CA / ACCESS Newswire / January 22, 2025 / ZeroPath Corp., a Y Combinator-backed cybersecurity company, today announced the public launch of its LLM-driven code security platform. The company was previously noted for using its platform to find critical zero-day vulnerabilities in major open-source projects. Alongside the launch, the company also announced the completion of its seed funding round led by SurgePoint Capital, with Y Combinator and angel investor Paul Graham both participating. ZeroPath's security testing platform, among the first of its kind, attempts to combine deep program analysis with large language models to detect more complex security vulnerabilities. The system has previously demonstrated remarkable success in identifying critical security flaws in large open-source repositories, including remote code execution vulnerabilities, authorizati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye